Search - tctmd.com

Displaying 1 - 20 of 48

Sort: Relevancy | Date

Anatomic Disease After PCI Linked With Worse Outcomes: VA CART

News Daily News

Anatomic Disease After PCI Linked With Worse Outcomes: VA CART

Michael O'Riordan

December 22, 2022

OSCAR Supports Rivaroxaban for Secondary VTE Prevention in Cancer

News Daily News

OSCAR Supports Rivaroxaban for Secondary VTE Prevention in Cancer

December 16, 2022

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

Myocarditis After COVID-19 Vaccination Less Serious Than Prepandemic Cases

News Daily News

Myocarditis After COVID-19 Vaccination Less Serious Than Prepandemic Cases

December 06, 2022

Slight Risk of Interstitial Lung Disease Seen With Certain DOACs

News Daily News

Slight Risk of Interstitial Lung Disease Seen With Certain DOACs

November 23, 2022

Exposure to Lead Linked to Risk of CVD Mortality: Strong Heart Study

News Daily News

Exposure to Lead Linked to Risk of CVD Mortality: Strong Heart Study

Michael O'Riordan

November 18, 2022

Partial Oral Antibiotic Regimen for Endocarditis Effective in Real World

News Conference News AHA 2022

Partial Oral Antibiotic Regimen for Endocarditis Effective in Real World

Michael O'Riordan

November 10, 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

News Conference News AHA 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

November 10, 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

News Conference News AHA 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

November 06, 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

News Conference News AHA 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

November 05, 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

Renal Function Affects Ticagrelor/Aspirin Impact on Recurrent Stroke: CHANCE-2

News Daily News

Renal Function Affects Ticagrelor/Aspirin Impact on Recurrent Stroke: CHANCE-2

Yael L. Maxwell

November 03, 2022

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

News Daily News

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

Michael O'Riordan

October 20, 2022

COVID Drug Paxlovid Interacts With Widely Used CV Meds: Review

News Daily News

COVID Drug Paxlovid Interacts With Widely Used CV Meds: Review

October 12, 2022

FFR/iFR No Help in CABG Surgery in SWEDEHEART Registry

News Conference News EACTS 2022

FFR/iFR No Help in CABG Surgery in SWEDEHEART Registry

Michael O'Riordan

October 07, 2022

Checking Cumulative High BP Exposure Hones CV Risk Prediction in Diabetes

News Daily News

Checking Cumulative High BP Exposure Hones CV Risk Prediction in Diabetes

September 14, 2022

VITAL Rhythm Data May Flip the Script on AF Screening in Women

News Daily News

VITAL Rhythm Data May Flip the Script on AF Screening in Women

September 08, 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

News Conference News ESC 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

September 01, 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

News Conference News ESC 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Michael O'Riordan

August 31, 2022

More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

News Conference News ESC 2022

INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

Michael O'Riordan

August 28, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.